SCHEMBL6131012

SCHEMBL6131012

c1cnnc(Cc2ccncc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
CYP11B1 P15538 6/20 0.38
CYP11B2 P19099 6/20 0.38
CYP3A4 P08684 6/20 0.38
CYP17A1 P05093 5/20 0.38
CYP19A1 P11511 3/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
ALDH1A1 P00352 2/20 0.37
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
CHRM1 P11229 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129775 0.85 ALDH1A1 (0.52) CYP1A2ALDH1A1CYP2D6CTDSP1SMN1; SMN2
SCHEMBL3076036 0.82 CYP1A2 (0.47) CYP1A2ALDH1A1HRH3CYP2D6CYP2C9
SCHEMBL28210941 0.80 CYP1A2 (0.38) CYP1A2ALDH1A1CYP2D6CTDSP1CHRM1
SCHEMBL29349000 0.80 ESR1 (0.48) CYP1A2ALDH1A1CTDSP1L3MBTL1
SCHEMBL28174339 0.76 LTA4H (0.52) CYP11B1CYP11B2CYP19A1ALDH1A1CYP2D6
SCHEMBL5407176 0.76 CYP1A2 (0.43) CYP1A2ALDH1A1HRH3CYP2D6CYP2C9
Hydrazine SCHEMBL11630131 0.73 LTA4H (0.49) CYP11B1CYP11B2ALDH1A1CYP2D6SMN1; SMN2
SCHEMBL29525303 0.73
SCHEMBL242473 0.73
SCHEMBL2750124 0.72 L3MBTL1 (0.63) CYP1A2CYP11B1CYP11B2ALDH1A1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050054647-A1 New pharmaceutical combination BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054647-A1 New pharmaceutical combination VEGFA, INHA, PGF CYP1A2 228/4885CYP11B1 86/4885CYP11B2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.